samedan logo
 
 
 
spacer
home > ebr > summer 2004 > the declaration of helsinki: protecting patient rights in biomedical research drug discovery technologies
PUBLICATIONS
European Biopharmaceutical Review

The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies

The Declaration of Helsinki is the world's most widely recognised source of ethical guidance for biomedical research. Since its adoption in 1964, it has become the pre-eminent ethical guidance on health care research. Adherence to it is required by the World Health Organization and by many national governments, who refer to its provisions in their legislation. Scientists are often criticised for carrying out research in developing countries without following the Declaration, and some organisations and companies sponsoring research request that researchers receiving funding abide by its requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Delon Human, Secretary General of the World Medical Association

Dr Delon Human has been Secretary General of the WMA since 1998. He is a former family physician from Pretoria, South Africa and a past president of a branch of the Medical Association of South Africa. He qualified as a family practitioner in 1985 and spent some time at the John Radcliffe Hospital in Oxford, England, conducting research in paediatric endocrinology. He then gained two further Masters degrees in Family Medicine and a Diploma in Child Health. In addition to his medical qualifications, Dr Human has also obtained an MBA from the European Business School.

spacer
Dr Delon Human
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the treatment of COVID-19.
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement